Ready to make money...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agreed!!!
As do I - GL to us both.
Harry - I see you are still here... I have added down and up. This is a no brainer here... so much fundamentally and technically strong here.
Yeh - No pomp no circumstance - just up... shorts covering - fundamentals lining up. Major upside to come - seriously undervalued. I am happy not see to see any posts here - means less games and more return. Still think you will see a buyout short term... fundamentals say its a real possibility if the probable acquirer’s I expect are at the table are willing and able to pay for it... This is a Technology and IP company - Technosphere and their IP has broad based application. JMHO
Bud... This is a delivery system and product engineering company and Big Pharma knows it. Multiple downstream revenue opportunities - you know of some but there are way many more.
This company is a platform.
A lot of outside people swarming around this company right now... AMGN, RLS, UTRH, Hooper...
JMHO
Someone is going to soon step up and pay big for this technology and IP. JMHO
Insiders own... 7,063,716 (23.65%)
Institutions own... 16,764,697 (56.12%)
79.77% controlled...
Float... 6,042,983 (20.23%)
They are working to get what’s left of the float and there is not much. JMHO
https://images.fintel.io/us-tcon-so.png
https://www.nasdaq.com/symbol/tcon/institutional-holdings
https://www.nasdaq.com/symbol/tcon/insider-trades
Tick tock...
SS
All I need to know...
https://images.fintel.io/us-tcon-so.png
Tick tock!
Bash away - but - at least get your numbers right. Btw - the revenue numbers you post here are incorrect at time of this posting.
Shorts are now on the danger side of trading here. Tick tock... Fundamentals are strengthening. Look for buyout or material advance - it will be one or the other. JMHO
I agree and just about as much as 95% of your posts. Jmho
Time for 2’s like I said yesterday - Tick Tock
At this point just cleaning up the under 2’s - this is going up as soon as that is complete and IMO near term based on today’s trading.
Lol... You’re hilarious. Drama. You’re soon going to be materially wrong. JMHO.
They worked all day to fill block orders at end of day as evidenced by the substantive volume increase in the past hour.
Nice 1.2M share buy at close you could see it mounting all day... with the push down out of the gate. Big block buying is occurring JMHO.
Interesting end of day... hmm.
Wedge formation in final phase - just a matter of time.
Accumulation is occurring here in a concerted way... mark this post.
I’m looking forward to seeing what’s coming here.
JMHO
One spark away from a complete train wreck for shorts...
I have a feeling it’s coming soon.
JMHO
Watch bounce back - shorts trying but they are cooked here. JMHO
TRACON Pharmaceuticals Announces Publication of Phase 1b Results for TRC105 in Combination with Inlyta® in Patients with Advanced or Metastatic RCC
Sep. 10, 2018 9:00 AM
GlobeNewswire
SAN DIEGO, Sept. 10, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced the publication of results from a Phase 1b clinical trial combining TRC105 with Inlyta® (axitinib) in patients with advanced or metastatic renal cell carcinoma (RCC). Dr. Toni Choueiri of the Dana Farber Cancer Institute and colleagues published these results in the peer-reviewed journal, The Oncologist (Epublication ahead of print is available at PubMed.gov through PubMed ID number 30190302), and Dr. Andrew Hahn of the Huntsman Cancer Institute and co-authors published an accompanying editorial (Epublication ahead of print is available at PubMed.gov through PubMed ID number 30139834). These data were previously presented at the European Society for Medical Oncology (ESMO) 2016 Congress (CACOX) in Copenhagen, Denmark.
The open-label dose escalation and expansion Phase 1b study enrolled a total of 18 patients (17 of whom were evaluable for response) who had received at least one prior line of therapy with a VEGF receptor tyrosine kinase inhibitor (VEGFR TKI). The median number of prior therapies in the group was three, with a range of one to six. All patients in the trial received a combination of TRC105 and Inlyta. The data are summarized in the table below.
Summary of Phase 1b Results for TRC105-Inlyta Combination in RCC
Patients ORR Stable
Disease Overall Disease
Control Median PFS Median PFS in Clear Cell
RCC Subset (n=12)
N = 17 29%
(5/17) 59%
(10/17) 88%
(15/17) 11.3 months 11.3 months
For comparison, in a separate trial, the objective response rate (ORR) seen in the large subgroup of VEGFR TKI-refractory patients treated with Inlyta (n=194) in the Inlyta AXIS Phase 3 study in second-line clear cell RCC patients was 11.3%, and median progression-free survival (PFS) was 4.8 months.
The publication also notes that plasma levels of TGF-ß receptor 3 (betaglycan) at baseline were significantly higher in patients who experienced a partial response, while levels of osteopontin were significantly lower at baseline for patients that achieved a partial response. Both markers correlated with time on study and their potential prognostic value are being investigated in the ongoing Phase 2b TRAXAR study. TRACON’s Phase 2b TRAXAR clinical trial of TRC105 in combination with Inlyta completed enrollment of 150 patients with advanced or metastatic RCC in Q3 2017 and top-line data are expected to be available in December 2018.
About the TRAXAR Phase 2b Clinical Trial in RCC
The Phase 2b TRAXAR clinical trial is a multicenter, open-label, randomized clinical trial of TRC105 in combination with Inlyta versus Inlyta in patients with advanced or metastatic RCC. The primary endpoint of the Phase 2b study is progression-free survival. Patients may have also failed one prior mTOR inhibitor and one prior immunotherapy. For additional information on this clinical trial, please visit www.clinicaltrials.gov, identifier NCT01806064.
About Carotuximab (TRC105)
TRC105 is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in a pivotal Phase 3 trial in angiosarcoma and multiple Phase 2 clinical trials, in combination with VEGF inhibitors, as well as in a Phase 1 trial with Opdivo. TRC105 has received orphan designation for the treatment of soft tissue sarcoma in both the U.S. and EU. The ophthalmic formulation of TRC105, DE-122, is currently in a randomized Phase 2 trial for patients with wet AMD. For more information about the clinical trials, please visit TRACON’s website at www.traconpharma.com/clinical_trials.php.
Settling out - time for green
Looking for next charge forward to break $2.80 then $3’s :)
Great volume - big interest... tick took.
My how quiet you’ve become - definitely a nice change.
SS
This is money here JMHO - just a matter of time.
A lot of buying. JMHO
Agreed!
Very good sign of what’s to come... JMHO
Low float, low market cap, tightly held - this will rocket.
Big block buying going on - 400K share lot today almost the same amount yesterday. Tick tock.
This float is substantively absorbed by insiders and institutions.
So much potential here. JMHO.
Tick tick shorts...
Insiders are now buying... I added more today. Just about ready to rock and roll here... JMHO
Great post.
Nope it’s not
Float is tight - institutions and employees/directors have loaded up at these prices.
I dipped my toe in here today... I like what I see - low float, at supporting floor and 5-6 key pivot points this year...
SS